Newly Listed Guardian Pharmacy Is Well Positioned In Highly Fragmented Market, Analyst Initiates With Buy Rating
Truist starts coverage on GRDN, indicating positive growth potential. Company services 174,000 residents through 50 pharmacies in 36 states. Estimated U.S. institutional pharmacy revenue is $24.8 billion in 2024. GRDN holds 12% market share and targets lucrative assisted living markets. Truist projects a price target of $22, initiating with a Buy rating.
View signal analysis